Abstract
A curative possibility for certain people with hematologic malignancies and sporadically for others with benign hematologic diseases is hematopoietic stem cell transplantation (HSCT). The advancement of HSCT techniques and supportive care has enabled a growing number of people to survive long-term. Nevertheless, these survivors are more likely to develop chronic, debilitating illnesses over the long term, such as early cardiovascular disease. Patients with cancer are more likely to experience side effects than the general population, and there is a strong correlation between traditional cardiovascular risk factors, and the risk of developing cardiovascular diseases. The HSCT can be divided into two categories: autologous and allogeneic. After allogenic HSCT, late adverse effects are more common. The occurrence of late-occurring vascular events, including atherosclerosis, myocardial infarction, cerebrovascular accidents, peripheral arterial disease, vasculitis, or cardiac events, including left ventricular dysfunction, myocarditis, valvular heart disease, conduction disorders, and pericardial diseases. These issues frequently arise earlier than would be anticipated. All patients should be screened with clinical history and diagnostic tools by a cardiologist and preferably a cardio-oncologist specialist. Conventional cardiovascular (CV) risk factors should be managed thoroughly pre-HSCT.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CAC score:
-
Coronary artery calcium score
- CAD:
-
Coronary artery disease
- CT:
-
Computed tumography
- CTA:
-
CT angiography
- CV:
-
Cardiovascular
- CVA:
-
Cerebrovascular accidents
- DM:
-
Diabetes mellitus
- ECG:
-
Electrocardigram
- FRS:
-
Framingham Risk Score
- GvHD:
-
Graft versus host disease
- HSCT:
-
Hematopoietic stem cell transplantation
- HTN:
-
Hypertension
- IHD:
-
Ischemic heart disease
- LV:
-
Left ventricular
- MI:
-
Myocardial infarction
- MRI:
-
Magnetic resonance imaging
- PAD:
-
Peripheral arterial disease
- RT:
-
Radiation therapy
- TBI:
-
Total body irradiation
References
Armenian SH, Bhatia S. Cardiovascular disease after hematopoietic cell transplantation–lessons learned. Haematologica. 2008;93(8):1132–6.
Armenian SH, Chow EJ. Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer. 2014;120(4):469–79.
Armenian SH, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1138–44.
Armenian SH, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood J Am Soc Hematol. 2012;120(23):4505–12.
Armenian SH, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transplant. 2017;23(2):201–10.
Bhatia S, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood J Am Soc Hematol. 2007;110(10):3784–92.
Biedermann BC, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. The Lancet. 2002;359(9323):2078–83.
Chow EJ, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med. 2011;155(1):21–32.
Erbel R, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56(17):1397–406.
Geng H-H, et al. The relationship between C-reactive protein level and discharge outcome in patients with acute ischemic stroke. Int J Environ Res Public Health. 2016;13(7):636.
Goldberg SL, et al. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998;16(12):3796–802.
Greenland P, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2010;56(25):e50–103.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.
Herrmann J. Cardio-oncology practice manual: a companion to Braunwald’s heart disease e-book. Elsevier Health Sciences; 2022.
Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev. 2005;13(2):80–6.
Leger KJ, et al. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer. 2018;124(7):1507–15.
Madjid, M, Willerson JY. Inflammatory markers in coronary heart disease. Br Med Bull. 2011;100(1).
Majhail NS, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013;19(10):1498–501.
Majhail N et al., Sociedade Brasileira de Transplante de Medula Ossea. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;47(3):348–71.
Mitchell JD, Lenihan DJ. Cardio-oncology: essentials for effective consultation. In: The Washington Manual Cardiology Subspecialty Consult, 2022.
Mulrooney DA, et al. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer. 2014;120(22):3536–44.
Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37(7):1923–32.
Tichelli A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood J Am Soc Hematol. 2007;110(9):3463–71.
Tichelli A, Bhatia S, Socié G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008;142(1):11–26.
Tichelli A et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Hhaematologica 2008;93(8):1203–210.
Versluys A, et al. Predictors and outcome of pericardial effusion after hematopoietic stem cell transplantation in children. Pediatr Cardiol. 2018;39:236–44.
Voros S et al. Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis. JACC: Cardiovasc Imag 2011;4(5): 537–48.
Weisdorf DJ et al. Late mortality in survivors of autologous hematopoietic cell. 2005.
Woods KM, et al. The prognostic significance of coronary CT angiography. Curr Cardiol Rep. 2012;14:7–16.
Yeboah J, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–95.
Zhao Y, et al. Cardiovascular complications in hematopoietic stem cell transplanted patients. J Personal Med. 2022;12(11):1797.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Razavi, S.M., Sarraf, M., Firouzi, A., Parkhideh, S., Sayad, M., Yalameh, A. (2024). Coronary Artery Disease in HSCT. In: Alizadehasl, A., Ghavamzadeh, A., Emami, A.H., Janbabaei, G., Khoda-Amorzideh, D. (eds) Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation . Springer, Cham. https://doi.org/10.1007/978-3-031-53659-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-031-53659-5_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-53658-8
Online ISBN: 978-3-031-53659-5
eBook Packages: MedicineMedicine (R0)